A Comparison of the Direct Costs and Cost Effectiveness of Serotonin Reuptake Inhibitors and Associated Adverse Drug Reactions
- 1 January 2004
- journal article
- research article
- Published by Springer Nature in CNS Drugs
- Vol. 18 (13) , 911-932
Abstract
Background:The economic burden of depression is known to be high and was estimated to be $US83.1 billion in 2000. Serotonin reuptake inhibitors (SRIs), including both selective serotonin reuptake...Keywords
This publication has 55 references indexed in Scilit:
- Cost Effectiveness of Representatives of Three Classes of Antidepressants Used in Major Depression in the UKPharmacoEconomics, 2004
- EscitalopramPharmacoEconomics, 2003
- Third-Generation AntidepressantsCNS Drugs, 2001
- Formulary Restriction of Selective Serotonin Reuptake Inhibitors for DepressionPharmacoEconomics, 2001
- FluoxetinePharmacoEconomics, 1998
- Clinical and Economic Comparison of Sertraline and Fluoxetine in the Treatment of DepressionPharmacoEconomics, 1998
- SertralinePharmacoEconomics, 1997
- ParoxetinePharmacoEconomics, 1995
- EuroQol©: health-related quality of life measurement. Results of the Swedish questionnaire exerciseHealth Policy, 1991
- Least absolute deviations estimation for the censored regression modelJournal of Econometrics, 1984